Solid organ transplantation of viral hepatitis C positive donor organs into viral hepatitis C negative recipients

Ann Marie Liapakis*, Richard N. Formica, Josh Levitsky

*Corresponding author for this work

Research output: Contribution to journalReview article

7 Citations (Scopus)

Abstract

Purpose of review Strategies are needed to reduce waitlist mortality and increase transplantation rates. Advances in hepatitis C therapy has allowed the transplant community to look toward utilization of grafts from hepatitis C viremic donors to expand the organ pool. Use of such grafts for hepatitis C-negative patients is being evaluated and debated, and early trial data are emerging. Recent findings Both hepatitis C antibody-positive/nucleic acid test-negative and viremic donors are currently underutilized. Outcomes for viral hepatitis C (HCV) viremic transplant recipients are improving in the setting of direct-acting antiviral therapy. Optimization of graft utilization from HCV ‘positive’ donors and expansion to use of viremic donors for HCV-negative recipients will likely reduce waitlist mortality and result in net overall reduction in healthcare expenditures. Summary Herein, we provide a review of recent advancements relating to hepatitis C in solid organ transplant and outline future directions. A primary future focus will be data collection of outcomes of transplantation of grafts from HCV ‘viremic’ donors to nonviremic recipients in formal clinical trial protocols.

Original languageEnglish (US)
Pages (from-to)257-263
Number of pages7
JournalCurrent opinion in organ transplantation
Volume23
Issue number2
DOIs
StatePublished - Jan 1 2018

Fingerprint

Organ Transplantation
Hepatitis C
Tissue Donors
Transplants
Clinical Protocols
Transplantation
Hepatitis C Antibodies
Mortality
Health Expenditures
Nucleic Acids
Antiviral Agents
Clinical Trials
Delivery of Health Care
Therapeutics

Keywords

  • Donor transmission
  • Hepatitis C
  • Nucleic acid testing
  • Solid organ transplantation

ASJC Scopus subject areas

  • Immunology and Allergy
  • Transplantation

Cite this

@article{ab1ffe02dba04454acc949f4df57a3bf,
title = "Solid organ transplantation of viral hepatitis C positive donor organs into viral hepatitis C negative recipients",
abstract = "Purpose of review Strategies are needed to reduce waitlist mortality and increase transplantation rates. Advances in hepatitis C therapy has allowed the transplant community to look toward utilization of grafts from hepatitis C viremic donors to expand the organ pool. Use of such grafts for hepatitis C-negative patients is being evaluated and debated, and early trial data are emerging. Recent findings Both hepatitis C antibody-positive/nucleic acid test-negative and viremic donors are currently underutilized. Outcomes for viral hepatitis C (HCV) viremic transplant recipients are improving in the setting of direct-acting antiviral therapy. Optimization of graft utilization from HCV ‘positive’ donors and expansion to use of viremic donors for HCV-negative recipients will likely reduce waitlist mortality and result in net overall reduction in healthcare expenditures. Summary Herein, we provide a review of recent advancements relating to hepatitis C in solid organ transplant and outline future directions. A primary future focus will be data collection of outcomes of transplantation of grafts from HCV ‘viremic’ donors to nonviremic recipients in formal clinical trial protocols.",
keywords = "Donor transmission, Hepatitis C, Nucleic acid testing, Solid organ transplantation",
author = "Liapakis, {Ann Marie} and Formica, {Richard N.} and Josh Levitsky",
year = "2018",
month = "1",
day = "1",
doi = "10.1097/MOT.0000000000000504",
language = "English (US)",
volume = "23",
pages = "257--263",
journal = "Current Opinion in Organ Transplantation",
issn = "1087-2418",
publisher = "Lippincott Williams and Wilkins",
number = "2",

}

Solid organ transplantation of viral hepatitis C positive donor organs into viral hepatitis C negative recipients. / Liapakis, Ann Marie; Formica, Richard N.; Levitsky, Josh.

In: Current opinion in organ transplantation, Vol. 23, No. 2, 01.01.2018, p. 257-263.

Research output: Contribution to journalReview article

TY - JOUR

T1 - Solid organ transplantation of viral hepatitis C positive donor organs into viral hepatitis C negative recipients

AU - Liapakis, Ann Marie

AU - Formica, Richard N.

AU - Levitsky, Josh

PY - 2018/1/1

Y1 - 2018/1/1

N2 - Purpose of review Strategies are needed to reduce waitlist mortality and increase transplantation rates. Advances in hepatitis C therapy has allowed the transplant community to look toward utilization of grafts from hepatitis C viremic donors to expand the organ pool. Use of such grafts for hepatitis C-negative patients is being evaluated and debated, and early trial data are emerging. Recent findings Both hepatitis C antibody-positive/nucleic acid test-negative and viremic donors are currently underutilized. Outcomes for viral hepatitis C (HCV) viremic transplant recipients are improving in the setting of direct-acting antiviral therapy. Optimization of graft utilization from HCV ‘positive’ donors and expansion to use of viremic donors for HCV-negative recipients will likely reduce waitlist mortality and result in net overall reduction in healthcare expenditures. Summary Herein, we provide a review of recent advancements relating to hepatitis C in solid organ transplant and outline future directions. A primary future focus will be data collection of outcomes of transplantation of grafts from HCV ‘viremic’ donors to nonviremic recipients in formal clinical trial protocols.

AB - Purpose of review Strategies are needed to reduce waitlist mortality and increase transplantation rates. Advances in hepatitis C therapy has allowed the transplant community to look toward utilization of grafts from hepatitis C viremic donors to expand the organ pool. Use of such grafts for hepatitis C-negative patients is being evaluated and debated, and early trial data are emerging. Recent findings Both hepatitis C antibody-positive/nucleic acid test-negative and viremic donors are currently underutilized. Outcomes for viral hepatitis C (HCV) viremic transplant recipients are improving in the setting of direct-acting antiviral therapy. Optimization of graft utilization from HCV ‘positive’ donors and expansion to use of viremic donors for HCV-negative recipients will likely reduce waitlist mortality and result in net overall reduction in healthcare expenditures. Summary Herein, we provide a review of recent advancements relating to hepatitis C in solid organ transplant and outline future directions. A primary future focus will be data collection of outcomes of transplantation of grafts from HCV ‘viremic’ donors to nonviremic recipients in formal clinical trial protocols.

KW - Donor transmission

KW - Hepatitis C

KW - Nucleic acid testing

KW - Solid organ transplantation

UR - http://www.scopus.com/inward/record.url?scp=85047563275&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85047563275&partnerID=8YFLogxK

U2 - 10.1097/MOT.0000000000000504

DO - 10.1097/MOT.0000000000000504

M3 - Review article

C2 - 29432255

AN - SCOPUS:85047563275

VL - 23

SP - 257

EP - 263

JO - Current Opinion in Organ Transplantation

JF - Current Opinion in Organ Transplantation

SN - 1087-2418

IS - 2

ER -